High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 1, 2011, Pages 239-245

  Heinz, Werner J ^a   Kahle, Kathrin ^a   Helle Beyersdorf, Annegret ^a   Schirmer, Diana ^a   Lenker, Ulrike ^a   Keller, Daniela ^a   Langmann, Peter ^a   Klinker, Hartwig ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Hepatocellular carcinoma; HPLC; Peritoneal fluid; Serum concentrations; Sorafenib; Validation

Indexed keywords

ETHER; SORAFENIB;

ANALYTIC METHOD; ANALYTICAL EQUIPMENT; ARTICLE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; DRUG PERITONEAL FLUID LEVEL; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER CELL CARCINOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ULTRAVIOLET SPECTROSCOPY; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; ASCITIC FLUID; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CARCINOMA, RENAL CELL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; HUMANS; KIDNEY NEOPLASMS; LIVER NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES; SENSITIVITY AND SPECIFICITY;

EID: 79959582091     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1474-y     Document Type: Article

References (24)

1. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109 (Pubitemid 39331023)
2. Keating GM, Santoro A (2009) Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 69:223-240
3. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312-3318
4. Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R (2006) Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12:7271-7278 (Pubitemid 46095398)
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
6. Benson AB 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX (2009) NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 7:350-391
7. Villanueva A, Minguez B, Forner A, Reig M, Llovet JM Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 61: 317-328
8. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907-1917 (Pubitemid 37518510)
9. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851-11858 (Pubitemid 46094197)
10. Strumberg D, Awada A, Hirte H, Clark JW, Seeber S, Piccart P, Hofstra E, Voliotis D, Christensen O, Brueckner A, Schwartz B (2006) Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome? Eur J Cancer 42:548-556 (Pubitemid 43227936)
11. Coleman J, Wrzosek T, Roman R, Peterson J, McAllister P (2001) Setting system suitability criteria for detectability in high-performance liquid chromatography methods using signal-to-noise ratio statistical tolerance intervals. J Chromatogr A 917:23-27 (Pubitemid 32391306)
12. Hartmann C, Smeyers-Verbeke J, Massart DL, McDowall RD (1998) Validation of bioanalytical chromatographic methods. J Pharm Biomed Anal 17:193-218 (Pubitemid 28261471)
13. Jain L, Gardner ER, Venitz J, Dahut W, Figg WD (2008) Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma. J Pharm Biomed Anal 46:362-367
14. Sparidans RW, Vlaming ML, Lagas JS, Schinkel AH, Schellens JH, Beijnen JH (2009) Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite. J Chromatogr B Analyt Technol Biomed Life Sci 877:269-276
15. Zhao M, Rudek MA, He P, Hafner FT, Radtke M, Wright JJ, Smith BD, Messersmith WA, Hidalgo M, Baker SD (2007) A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci 846:1-7
16. Afify S, Rapp UR, Hogger P (2004) Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serum. J Chromatogr B Analyt Technol Biomed Life Sci 809:99-103 (Pubitemid 38998425)
17. Blanchet B, Billemont B, Cramard J, Benichou AS, Chhun S, Harcouet L, Ropert S, Dauphin A, Goldwasser F, Tod M (2009) Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal 49:1109-1114
18. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ (2005) Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11:5472-5480 (Pubitemid 41060823)
19. Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, Strumberg D, Brendel E, Haase CG, Schwartz B, Piccart M (2005) Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92:1855-1861 (Pubitemid 40826133)
20. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K (2008) Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99:159-165 (Pubitemid 350239045)
21. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293-4300 (Pubitemid 46630787)
22. Chen K-F, Yu H-C, Liu T-H, Lee S-S, Chen P-J, Cheng A-L Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J Hepatol 52: 88-95
23. Mross K, Steinbild S, Baas F, Gmehling D, Radtke M, Voliotis D, Brendel E, Christensen O, Unger C (2007) Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer 43:55-63 (Pubitemid 46054474)
24. Piguet AC, Radojevic V, Afthinos M, Hora C, Ledermann M, Saar B, Dufour JF (2009) 536 The combination everolimus (RAD001) plus sorafenib is superior to sorafenib monotherapy in the treatment of hepatocellular carcinoma. J Hepatol 50:S199-S200